SCHEDULE 13G/A: Bain Capital Life Sciences Reports 7.5% Stake in Dianthus

BCLS Fund III Investments, LP, part of Bain Capital Life Sciences, reported a 7.5% beneficial ownership stake in Dianthus Therapeutics, Inc., comprising common stock and pre-funded warrants.

Summary

• BCLS Fund III Investments, LP, a Delaware limited partnership, has filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Dianthus Therapeutics, Inc.
• As of June 30, 2025, the Reporting Person beneficially owned an aggregate of 2,482,250 shares of Dianthus Therapeutics, Inc. Common Stock.
• This ownership consists of 1,481,917 shares of Common Stock and a pre-funded warrant to purchase up to 1,000,333 shares of Common Stock.
• The aggregate beneficial ownership represents 7.5% of the outstanding Common Stock of Dianthus Therapeutics, Inc.
• The percentage is calculated based on 32,176,482 shares of Common Stock outstanding as of June 30, 2025, as reported by the Issuer in its Form 10-Q, plus the 1,000,333 shares issuable upon warrant exercise.
• Bain Capital Life Sciences Investors, LLC (BCLSI) may be deemed to share voting and dispositive power over these securities.
• The Reporting Person certified that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Schedule 13G is a passive disclosure, the presence of a significant stake by a reputable institutional investor like Bain Capital Life Sciences can be interpreted as a vote of confidence in the company's value and future prospects.

Positives

• The disclosure of a significant 7.5% stake by a prominent institutional investor like Bain Capital Life Sciences may signal confidence in Dianthus Therapeutics, Inc.'s long-term prospects.
• The continued holding of a substantial position by a sophisticated investor can be viewed positively by the market.

Risks

• The Reporting Person is prohibited from exercising the pre-funded warrant if, as a result of such exercise, beneficial ownership would exceed 9.99% of the total number of shares of Common Stock then issued and outstanding, limiting their ability to increase their stake beyond this threshold through warrant conversion.

Future Outlook

The Reporting Person's ability to fully exercise its pre-funded warrant is subject to a beneficial ownership cap, preventing them from owning more than 9.99% of the outstanding Common Stock immediately after exercise.

Management Comments

• Ricky Sun, Partner of Bain Capital Life Sciences Investors, LLC, certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under SEC rules.

Industry Context

This filing highlights continued institutional investor interest in the biotechnology sector, with a specialized life sciences fund maintaining a significant stake in a therapeutic company. Such investments are common as funds seek to capitalize on potential growth in innovative drug development.

Stakeholder Impact

• Shareholders: The presence of a significant institutional investor like Bain Capital Life Sciences may provide a level of stability and confidence, potentially attracting further investment and validating the company's strategy.
• Management: Continued institutional backing can support management's strategic initiatives and provide access to capital markets.

Key Dates

Keywords

Dianthus Therapeutics, Bain Capital Life Sciences, BCLS Fund III Investments, Schedule 13G, Beneficial Ownership, Common Stock, Pre-funded Warrant, Biotechnology Investment, Institutional Investor